Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02457819 · ClinicalTrials.gov registry record · Phase 3
Dasotraline Pediatric Extension Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 237
- Enrollment target
NCT02457819: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT02457819 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 237 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02457819, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 237 participants
- Enrollment target
Study Summary
This is an open label 26 week extension study for subjects who completed SEP360-202.
Primary Outcome
Overall adverse events, AEs , serious adverse envents,(or SAEs), and AEs (or SAEs) leading to discontinuation.
Interventions
- DRUG Dasotraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2015-06-30 |
| Est. Completion | 2017-02-02 |
| Phase | Phase 3 |
What the finished NCT02457819 record still lists
NCT02457819 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which Dasotraline is the first listed.
NCT02457819 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02457819 about?
NCT02457819 is a clinical study titled "Dasotraline Pediatric Extension Study". This is an open label 26 week extension study for subjects who completed SEP360-202.
What is the current status of trial NCT02457819?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 237 participants. The study started on 2015-06-30. Estimated completion is 2017-02-02.
What interventions are being tested in trial NCT02457819?
The interventions under investigation include: Dasotraline (DRUG).
Who is sponsoring clinical trial NCT02457819?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02457819's enrollment target sits among peer trials
237 1293rd of 2000 higher than 707 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI